1.Clinical study of combination treatment with Clofazimine and others for patients with multidrug-resistant tuberculosis
Jianwu ZHANG ; Fang WANG ; Yanbo WANG ; Yanyan ZAN ; Shoujie JIA
Chinese Journal of Biochemical Pharmaceutics 2016;36(12):103-106,110
Objective To evaluate the clinical efficacy and safety of combination treatment with clofazimine ( Cfz ) and other antituberculosis drugs for patients with multidrug-resistant tuberculosis(MDR-TB).Methods 32 cases of MDR-TB patients were treated with combination regimens that included clofaziminefrom October 2011 to September 2016 in our hospitol,according to the history of drug use and drug susceptibility test results using individualized chemotherapy,the starting dose of clofazimine was 0.1 g/day,oral,some patients with adverse reactions and tolerance adjusted to 0.05 g/day,treatment for the last 12 months for three consecutive sputum mycobacterium tuberculosis culture and sputum smear acid-fast bacilli were cured,observe the clinical efficacy and safety.Results After treatment with the combined regimen,56.2%(18/32) of patients were cured,43.8%(14/32) of patients failed treatment, there was no statistically significant difference in the number of drug-resistant patients before and after CFZ treatment,there was no statistically significant difference between the time of failure and the time of CFZ treatment,after taking CFZ combined with anti-tuberculosis program,the number of drug users was statistically significant of patients cured and failed (P<0.05).The average time of sputum culture inversion was 16w.90.6% (29/32) of patients with adverse reactions,mainly including skin color change,ichthyosis and gastrointestinal tract and other adverse reactions, through dose adjustment and symptomatic treatment to continue treatment.The average duration of treatment with clofazimine was about 13 months.ConclusionClofazimine was welltolerated,combination treatment with Clofazimine and others for patients with MDR-TBhave better efficacy .
2.Extraction-purification of pueraia isoflavone and soyisoflavones from Radix Puerariae lobatae by inner ebullition
Shoujie JIA ; Huadong XU ; Tengyou WEI ; Dankui LIAO ; Zhangfa TONG
Chinese Traditional Patent Medicine 1992;0(10):-
AIM:To extract pueraia isoflavone and soyisoflavones with n-butanol by means of inner ebullition from Radix puerariae lobatae.METHODS:A little ethanol was first used to saturate the powder of Radix puerariae lobatae to make the pueraia isoflavone desorbed adequately,and then hot n-Butanol solution was added to make the ethanol inside Radix puerariae lobatae begin to boil and the extraction was intensified.Based on different solubility of pueraia isoflavone and soyisoflavones in n-Butanol,when solvent vaporized,the soyisoflavones were separated and then the pueraia isoflavone by step vaporizeing on centrating crystal.RESULTS:80 mL of 60% ethanol,saturating time 20 min,600 mL n-Butanol including 20% water,at the temperature of 90 ℃,the yield of total isoflavone was 11.3 %.When 90% solvent vaporized,the ratio of quality of the soyisoflavones and pueraia isoflavone was 1∶3.The puerarin and daidzin's purity reached 46.0% and 6.12% by the HPLC respectively.CONCLUSION:The technology of inner ebullition extraction and solvent vaporizing crystal separation are simple,which provide industry production basis for pueraia isoflavone and soyisoflavones.